Investigating leucine's effects on midlife depression

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to explore the impact of a 6-week leucine challenge on brain chemistry, connectivity, and behavior in individuals suffering from midlife depression. Participants will be divided into two groups, with one receiving leucine supplements and the other receiving an active comparator, lysine. The research focuses on the relationship between inflammation and depression, particularly through the kynurenine pathway, which may produce toxic substances affecting brain function. Brain scans and symptom assessments will be utilized to evaluate the effectiveness of leucine in improving mental health outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Able and willing to provide informed consent
* Diagnosis of major depression per Structured Interview for DSM-V (SCID-V)
* Moderate to severe depression- Inventory of Depressive Symptoms - Self Reported (IDS-SR score \>34).
* SHAPS score \>30 on the 0-56 scale
* Body mass index (BMI) between 20-35 kg/m2
* Plasma CRP \>1 mg/L
* No contraindications to MRI
* Availability of friends or family for transportation after lumbar puncture procedure
* Clinically significant findings on EKG
* Patient Health Questionnaire (PHQ-9) score greater than 10
* Willingness to adopt contraceptive measures. Persons exempt from contraception requirements are:

  * Persons assigned male at birth
  * Persons assigned female at birth who:

    * have undergone a hysterectomy or bilateral oophorectomy; or
    * have been naturally postmenopausal for at least 24 consecutive months (i.e., has NOT had menses at any time in the preceding 24 consecutive months)

Exclusion Criteria:

* Leucine-Specific:

  * History of maple syrup urine disease
  * Risk of hypoglycemia (unstable diabetes)
  * History of vitamin B6 deficiency, relative
* Lysine-Specific:

  * On calcium supplements, relative
  * History of renal/gall stones (could cleared by a primary care provider)
* Cognitive:

  --Cognitive impairment (MMSE score \<28)
* Psychiatric Disorders:

  * Lifetime diagnosis of psychotic disorders.
  * Current mania/hypomania.
  * Substance use disorder in the last 6 months.
  * Active suicidal ideation:
  * Psychiatric hospitalization in the past year.
  * Suicide attempts within the last five years.
  * Scores \>3 on the Columbia Suicide Severity Rating Scale (C-SSRS)
  * Binge eating in the absence of mood symptoms increases.
  * Primary diagnosis of severe DSM-V79 anxiety disorders.
  * Primary diagnosis of DSM-V PTSD (if severity exceeds major depression).
  * Primary diagnosis of DSM-V obsessive-compulsive disorders.
  * Significant personality disorders with multiple hospitalizations or suicide attempts.
  * Developmental disorders (e.g., ADHD).
* Concomitant medications:

  * Immune-active medications (e.g., non-steroidal anti-inflammatory agents).
  * Antibiotics and immunizations in the past 2 weeks.
  * Topical or inhaled steroids within the past week.
  * Oral/parenteral steroids in the last 6 months.
  * Supplements that impact the immune system (e.g., omega-3, probiotics) within the past 2 weeks.
  * Psychotropic medications within the last 4 weeks (8 weeks for fluoxetine).
  * Daily use of sedative-hypnotics, benzodiazepines, and opiates.
* Medical Disorders:

  * Unstable medical disorders (frequent provider or medication changes).
  * Lifetime diagnosis/treatment of cancers (excluding basal cell carcinoma).
  * Lifetime diagnosis/treatment of autoimmune disorders.
  * Lifetime exposure to chemotherapeutic agents.
* MRI Considerations:

  \-- Location and quantity of metallic objects safe to MR
* Concomitant Treatment for Depression:

  \-- Treatments with antidepressant medications or those with antidepressant effects (dopamine supplements).
* Treatment for General Medical Conditions (GMCs):

  * Stabilized medications are allowed if maintained at the same dose during the trial.
  * Multiple recent changes in concomitant medications reviewed by the study PI
* Population

  * Pregnant women.
  * Children.
  * Prisoners.
  * Individuals unable to consent

Where it's running

• Emory University Hospital
  Atlanta, Georgia, United States Recruiting

Study contacts

• Principal investigator: Ebrahim Haroon, MD — Emory University
• Study coordinator: Ebrahim Haroon, MD
• Email: eharoon@emory.edu
• Phone: (404) 727-8229

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can tACS modulate motivation and reward signals in cannabis use disorder and depression

  We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.

  Recruiting Florida State University · Tallahassee, Florida and 1 other locations · NCT07924852

• Neural links for real-world emotions in mood and anxiety

  Researchers are testing how real-life emotional moments relate to brain activity and stress responses in young adults with mood and anxiety symptoms, using smartphones, self-reports, tasks, and MRI.

  Recruiting University of Miami · Coral Gables, Florida · NCT07891624

• EEG-Guided TMS for Adults With Depression

  This study tests whether delivering intermittent theta burst stimulation (iTBS) timed to brain waves using EEG can improve treatment for adults with major depressive disorder who have not responded to usual antidepressants.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT07862205

• iTBS to help anhedonia in depression (dual left DLPFC + OFC or left DLPFC alone)

  A brain stimulation study tests whether intermittent theta burst stimulation can help people with major depression who have anhedonia, using both dual-target (left DLPFC and OFC) and single-target (left DLPFC) approaches.

  Recruiting Central South University · Changsha, Hunan · NCT07813169

• One Day of Ultra-Accelerated TMS With a Dose of NRX-101 for Major Depression

  This study tests whether a single day of rapid TMS plus NRX-101 can help people with moderate to severe depression see improvement over six weeks.

  Recruiting Early Phase 1 Mclean Hospital · Belmont, Massachusetts · NCT07785102

• EEG microstates and inflammatory markers in treatment-resistant depression patients undergoing ECT

  This study tests how electroconvulsive therapy affects brain activity patterns seen in EEG and inflammatory biomarkers in adults with treatment-resistant major depression.

  Recruiting Istanbul University - Cerrahpasa · Istanbul, Bakırköy · NCT07748091

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.